Double targeted therapy in refractory SpA/PsA. 76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics. Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit. ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX

Starting the “Imaging innovation in RA” session with #OP0343: Singapore investigators developed an AI-based thermography model to detect RA wrist inflammation using thermal hand images, achieving an AUC of 0.87 against ultrasound power doppler as reference. #EULAR2026 @RheumNow https://t.co/2v39E6VOWB

10yr ffup data on 49pts from the OG CRESPA study (GOL vs PBO in very early pSpA): 81.6% (40/49) were in clinical remission 15 pts on drug-free remission 21 pts w/remission on meds still on GOL, no unSSAEs Early aggressive tx is key! AbsPOS0931 @RheumNow #EULAR2026 https://t.co/HrTF5XtAZt

This study describes the SIJ differences in axSpA vs. non-axSpA pts with CBP axSpA: BME w/ widespread distribution & inflamm⬇️ over time non-axSpA: BME rare or limited only to ventral & middle superior sacrum Findings may improve MRI ID of axSpa AbsPOS0193 @RheumNow #EULAR2026 https://t.co/7eiHQOOIWs

Gecacitinib 100mg BiD vs PBO in active r-axSpA: Met primary endpt ASAS40 at wk 16 showing efficacy of gecacitinib vs. PBO (51.9%vs12.9%,p<0.0001) Gecacitinib showed ⬆️ improvements in ASDAS-CRP, physical fnxn, spinal mobility & QOL Promising tx. AbsOP0240 @RheumNow #EULAR2026 https://t.co/FytoRgxvnG

Don't miss a single moment of #EULAR2026—RheumNow is bringing you comprehensive, real-time coverage from June 3-6. Our trusted global faculty will cut through the noise, translating the latest breaking data and complex science into high-yield, practical insights. Whether you are https://t.co/isBsTVnEcK

#OP0337 In 48-week WILLOW🌳 LTE, oral TLR7/8 inhibitor enpatoran showed sustained improvements in cutaneous lupus activity with high CLASI-50/70 response rates and consistent safety profile across doses. Encouraging long-term data for CLE/SLE skin disease. #EULAR2026 @RheumNow https://t.co/6y0HjaTMqh

#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE #lupus @RheumNow https://t.co/0Plpy6c8At

Personalized #RA treatment based on Ab status and early response: better than routine care? PRIMERA RCT (n=308) says not yet. b/tsDMARD use at 10m: 21% tailored vs 17% routine. Disease activity curves identical. MTX + T2T still the standard for most. @RheumNow #EULAR2026 POS0258 https://t.co/W9FVoqTcMq

One of the main changes in the 2025 update on the EULAR guidelines for imaging in SpA is that of MRI replacing CR as the initial imaging modality while CR & low dose CT of SIJs became alternative modalities in the absence of or if with CIs to MRI AbsPOS0682 @RheumNow #EULAR2026 https://t.co/bj2NWKnIGf

Treat-to-target in inflammatory arthritis recommended by every guideline. Followed in only 40% of SpA visits. The main reason was activity simply wasn’t documented using a validated index. You can’t target what you don’t measure. Abstr 0351 @ RheumNow #EULAR2026 #axSpA #PsA https://t.co/VAcoZfCXsR

New Insights in Gout Clinical Management https://t.co/Eo63NUhaY2 https://t.co/oHZG1c1LhL